ERBB2 and breast carcinoma: However, clinical reports of nodal response after neoadjuvant dual anti‐HER2 blockade remain insufficient for node‐positive HER2‐breast cancer despite the addition of dual HER2‐targeted therapy to the armamentarium against HER2 breast cancer.